MEDICLIN AG (MED.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:MED - DE0006595101 - Common Stock
3.82 EUR
+0.1 (+2.69%)
MED gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 32 industry peers in the Health Care Providers & Services industry. MED scores excellent on profitability, but there are some minor concerns on its financial health. MED may be a bit undervalued, certainly considering the very reasonable score on growth
1. Profitability
1.1 Basic Checks
In the past year MED was profitable.
In the past year MED had a positive cash flow from operations.
In multiple years MED reported negative net income over the last 5 years.
Each year in the past 5 years MED had a positive operating cash flow.
1.2 Ratios
MED has a Return On Assets of 3.85%. This is in the better half of the industry: MED outperforms 65.63% of its industry peers.
MED has a better Return On Equity (14.15%) than 71.88% of its industry peers.
MED's Return On Invested Capital of 7.06% is fine compared to the rest of the industry. MED outperforms 68.75% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for MED is below the industry average of 7.02%.
The 3 year average ROIC (3.46%) for MED is below the current ROIC(7.06%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.85% | ||
| ROE | 14.15% | ||
| ROIC | 7.06% |
ROA(3y)0.85%
ROA(5y)0.34%
ROE(3y)3.39%
ROE(5y)1.18%
ROIC(3y)3.46%
ROIC(5y)2.35%
1.3 Margins
Looking at the Profit Margin, with a value of 4.40%, MED is in the better half of the industry, outperforming 78.13% of the companies in the same industry.
In the last couple of years the Profit Margin of MED has grown nicely.
With a decent Operating Margin value of 8.52%, MED is doing good in the industry, outperforming 78.13% of the companies in the same industry.
In the last couple of years the Operating Margin of MED has grown nicely.
With an excellent Gross Margin value of 84.08%, MED belongs to the best of the industry, outperforming 84.38% of the companies in the same industry.
MED's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.52% | ||
| PM (TTM) | 4.4% | ||
| GM | 84.08% |
OM growth 3Y67.11%
OM growth 5Y19.19%
PM growth 3Y148.06%
PM growth 5Y18.19%
GM growth 3Y0.37%
GM growth 5Y0.18%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so MED is still creating some value.
Compared to 1 year ago, MED has about the same amount of shares outstanding.
MED has about the same amout of shares outstanding than it did 5 years ago.
The debt/assets ratio for MED has been reduced compared to a year ago.
2.2 Solvency
MED has an Altman-Z score of 1.59. This is a bad value and indicates that MED is not financially healthy and even has some risk of bankruptcy.
MED's Altman-Z score of 1.59 is on the low side compared to the rest of the industry. MED is outperformed by 65.63% of its industry peers.
MED has a debt to FCF ratio of 9.63. This is a negative value and a sign of low solvency as MED would need 9.63 years to pay back of all of its debts.
MED has a Debt to FCF ratio of 9.63. This is comparable to the rest of the industry: MED outperforms 53.13% of its industry peers.
A Debt/Equity ratio of 1.69 is on the high side and indicates that MED has dependencies on debt financing.
The Debt to Equity ratio of MED (1.69) is worse than 65.63% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.69 | ||
| Debt/FCF | 9.63 | ||
| Altman-Z | 1.59 |
ROIC/WACC1.46
WACC4.84%
2.3 Liquidity
A Current Ratio of 1.93 indicates that MED should not have too much problems paying its short term obligations.
MED's Current ratio of 1.93 is amongst the best of the industry. MED outperforms 90.63% of its industry peers.
A Quick Ratio of 1.89 indicates that MED should not have too much problems paying its short term obligations.
The Quick ratio of MED (1.89) is better than 93.75% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.93 | ||
| Quick Ratio | 1.89 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 414.18% over the past year.
The Earnings Per Share has been growing by 20.79% on average over the past years. This is a very strong growth
MED shows a small growth in Revenue. In the last year, the Revenue has grown by 3.40%.
MED shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 2.19% yearly.
EPS 1Y (TTM)414.18%
EPS 3Y157.01%
EPS 5Y20.79%
EPS Q2Q%7.67%
Revenue 1Y (TTM)3.4%
Revenue growth 3Y3.65%
Revenue growth 5Y2.19%
Sales Q2Q%7.96%
3.2 Future
The Earnings Per Share is expected to grow by 20.09% on average over the next years. This is a very strong growth
MED is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 3.42% yearly.
EPS Next Y62.2%
EPS Next 2Y28.31%
EPS Next 3Y20.09%
EPS Next 5YN/A
Revenue Next Year5.05%
Revenue Next 2Y3.88%
Revenue Next 3Y3.42%
Revenue Next 5YN/A
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
MED is valuated cheaply with a Price/Earnings ratio of 5.16.
MED's Price/Earnings ratio is rather cheap when compared to the industry. MED is cheaper than 100.00% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 27.19. MED is valued rather cheaply when compared to this.
The Price/Forward Earnings ratio is 5.60, which indicates a rather cheap valuation of MED.
Based on the Price/Forward Earnings ratio, MED is valued cheaper than 100.00% of the companies in the same industry.
MED is valuated cheaply when we compare the Price/Forward Earnings ratio to 23.92, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.16 | ||
| Fwd PE | 5.6 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of MED indicates a rather cheap valuation: MED is cheaper than 93.75% of the companies listed in the same industry.
MED's Price/Free Cash Flow ratio is rather cheap when compared to the industry. MED is cheaper than 87.50% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 3.9 | ||
| EV/EBITDA | 2.88 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
MED has a very decent profitability rating, which may justify a higher PE ratio.
MED's earnings are expected to grow with 20.09% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.08
PEG (5Y)0.25
EPS Next 2Y28.31%
EPS Next 3Y20.09%
5. Dividend
5.1 Amount
MED has a Yearly Dividend Yield of 1.13%.
Compared to an average industry Dividend Yield of 1.57, MED has a dividend in line with its industry peers.
Compared to an average S&P500 Dividend Yield of 1.92, MED's dividend is way lower than the S&P500 average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.13% |
5.2 History
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
DPN/A
EPS Next 2Y28.31%
EPS Next 3Y20.09%
FRA:MED (1/12/2026, 1:08:58 PM)
3.82
+0.1 (+2.69%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners0.96%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap181.45M
Revenue(TTM)797.34M
Net Income(TTM)35.05M
Analysts80
Price Target5.87 (53.66%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.13% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)22.34%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)6.4%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.48%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.16 | ||
| Fwd PE | 5.6 | ||
| P/S | 0.23 | ||
| P/FCF | 3.9 | ||
| P/OCF | 1.88 | ||
| P/B | 0.73 | ||
| P/tB | 0.81 | ||
| EV/EBITDA | 2.88 |
EPS(TTM)0.74
EY19.37%
EPS(NY)0.68
Fwd EY17.85%
FCF(TTM)0.98
FCFY25.63%
OCF(TTM)2.04
OCFY53.28%
SpS16.79
BVpS5.21
TBVpS4.7
PEG (NY)0.08
PEG (5Y)0.25
Graham Number9.32
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.85% | ||
| ROE | 14.15% | ||
| ROCE | 9.1% | ||
| ROIC | 7.06% | ||
| ROICexc | 9.61% | ||
| ROICexgc | 10.05% | ||
| OM | 8.52% | ||
| PM (TTM) | 4.4% | ||
| GM | 84.08% | ||
| FCFM | 5.83% |
ROA(3y)0.85%
ROA(5y)0.34%
ROE(3y)3.39%
ROE(5y)1.18%
ROIC(3y)3.46%
ROIC(5y)2.35%
ROICexc(3y)4.47%
ROICexc(5y)3.03%
ROICexgc(3y)4.72%
ROICexgc(5y)3.22%
ROCE(3y)4.46%
ROCE(5y)3.03%
ROICexgc growth 3Y64.29%
ROICexgc growth 5Y26.18%
ROICexc growth 3Y68.25%
ROICexc growth 5Y27.23%
OM growth 3Y67.11%
OM growth 5Y19.19%
PM growth 3Y148.06%
PM growth 5Y18.19%
GM growth 3Y0.37%
GM growth 5Y0.18%
F-Score8
Asset Turnover0.88
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.69 | ||
| Debt/FCF | 9.63 | ||
| Debt/EBITDA | 3.49 | ||
| Cap/Depr | 96.09% | ||
| Cap/Sales | 6.29% | ||
| Interest Coverage | 3.18 | ||
| Cash Conversion | 80.47% | ||
| Profit Quality | 132.66% | ||
| Current Ratio | 1.93 | ||
| Quick Ratio | 1.89 | ||
| Altman-Z | 1.59 |
F-Score8
WACC4.84%
ROIC/WACC1.46
Cap/Depr(3y)56.34%
Cap/Depr(5y)45.08%
Cap/Sales(3y)4.78%
Cap/Sales(5y)4.13%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)414.18%
EPS 3Y157.01%
EPS 5Y20.79%
EPS Q2Q%7.67%
EPS Next Y62.2%
EPS Next 2Y28.31%
EPS Next 3Y20.09%
EPS Next 5YN/A
Revenue 1Y (TTM)3.4%
Revenue growth 3Y3.65%
Revenue growth 5Y2.19%
Sales Q2Q%7.96%
Revenue Next Year5.05%
Revenue Next 2Y3.88%
Revenue Next 3Y3.42%
Revenue Next 5YN/A
EBIT growth 1Y281.51%
EBIT growth 3Y73.21%
EBIT growth 5Y21.8%
EBIT Next Year143.72%
EBIT Next 3Y33.62%
EBIT Next 5YN/A
FCF growth 1Y196.83%
FCF growth 3Y-17.96%
FCF growth 5Y7.78%
OCF growth 1Y96.85%
OCF growth 3Y-0.57%
OCF growth 5Y2.97%
MEDICLIN AG / MED.DE FAQ
What is the ChartMill fundamental rating of MEDICLIN AG (MED.DE) stock?
ChartMill assigns a fundamental rating of 6 / 10 to MED.DE.
Can you provide the valuation status for MEDICLIN AG?
ChartMill assigns a valuation rating of 9 / 10 to MEDICLIN AG (MED.DE). This can be considered as Undervalued.
Can you provide the profitability details for MEDICLIN AG?
MEDICLIN AG (MED.DE) has a profitability rating of 7 / 10.
Can you provide the PE and PB ratios for MED stock?
The Price/Earnings (PE) ratio for MEDICLIN AG (MED.DE) is 5.16 and the Price/Book (PB) ratio is 0.73.
What is the financial health of MEDICLIN AG (MED.DE) stock?
The financial health rating of MEDICLIN AG (MED.DE) is 4 / 10.